PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients

Condition(s) targeted: Prostate Cancer; Obesity

Phase: N/A

Status: Recruiting

Sponsored by: AstraZeneca

Official(s) and/or principal investigator(s):
Istvan Buzogany, Principal Investigator, Affiliation: Budapest City's Local Government "Péterfy Sándor" Hospital and Ambulatory Clinic

Overall contact:
Clinical Study Information Clinical Study Information, Phone: +36 23 517 300, Email: csaba.csongvai@astrazeneca.com

The reports on relationship of obesity and biochemical or clinical recurrence of prostate cancer are controversial. Several reports have shown that obesity is associated with increased risk of biochemical or clinical failure after radical prostatectomy. Other prospective studies have shown no adverse effect of obesity on long-term outcomes after prostatectomy. Limited reports are available on the impact of obesity on prostate cancer progression after radiotherapy. Primary: to assess percentage recurrence rate among normal weight and overweight or obese prostate cancer patients treated by adjuvant Zoladex therapy. Secondary: to determine the Quality of Life differences among normal and overweight or obese prostate cancer patients by a Quality of Life questionnaire

Official title: PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients Assessment of the Correlation Between Body Mass Index and Recurrence Among Zoladex Treated Prostate Cancer Patients

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: Percentage recurrence rate among normal weight and overweight or obese prostate cancer patients treated by adjuvant Zoladex therapy.

Secondary outcome: Quality of Life differences among normal and overweight or obese prostate cancer patients by a Quality of Life questionnaire

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Male.

Criteria:

Inclusion Criteria:

- Histologically proven prostate cancer patients being on adjuvant Zoladex treatment

after primary therapy or on adjuvant therapy without primary curative therapy

Clinical Study Information Clinical Study Information, Phone: +36 23 517 300, Email: csaba.csongvai@astrazeneca.com

Research Site, Baja, Hungary; Recruiting

Research Site, Barcs, Hungary; Recruiting

Research Site, Bekes, Hungary; Recruiting

Research Site, Bekescsaba, Hungary; Recruiting

Research Site, Budapest, Hungary; Recruiting

Research Site, Csongrad, Hungary; Recruiting

Research Site, Debrecen, Hungary; Recruiting

Research Site, Dunaharaszti, Hungary; Recruiting

Research Site, Dunaujvaros, Hungary; Recruiting

Research Site, Gyor, Hungary; Recruiting

Research Site, Gyula, Hungary; Recruiting

Research Site, Helvecia, Hungary; Recruiting

Research Site, Jaszbereny, Hungary; Recruiting

Research Site, Kaposvar, Hungary; Recruiting

Research Site, Kecskemet, Hungary; Recruiting

Research Site, Kiskunhalas, Hungary; Recruiting

Research Site, Koszarhegy, Hungary; Recruiting

Research Site, Mako, Hungary; Recruiting

Research Site, Miskolc, Hungary; Recruiting

Research Site, Nagyvenyim, Hungary; Recruiting

Research Site, Nyiregyhaza, Hungary; Recruiting

Research Site, Nyirpazony, Hungary; Recruiting

Research Site, Oroshaza, Hungary; Recruiting

Research Site, Papa, Hungary; Recruiting

Research Site, Pecs, Hungary; Recruiting

Research Site, Salgotarjan, Hungary; Recruiting

Research Site, Szeged, Hungary; Recruiting

Research Site, Szekesfehervar, Hungary; Recruiting

Research Site, Szekszard, Hungary; Recruiting

Research Site, Szentendre, Hungary; Recruiting

Research Site, Szolnok, Hungary; Recruiting

Research Site, Szombathely, Hungary; Recruiting

Research Site, Tiszafoldvar, Hungary; Recruiting

Research Site, Veszprem, Hungary; Recruiting

Starting date: November 2009
Last updated: March 4, 2010